14 years of historical data (2011–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ultragenyx Pharmaceutical Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.3B | $3.8B | $3.5B | $3.2B | $5.7B | $8.4B | $2.4B | $2.2B | $2.0B | $2.8B | $4.1B |
| Enterprise Value | $2.1B | $3.7B | $3.3B | $3.1B | $5.4B | $7.8B | $2.0B | $2.1B | $1.9B | $2.6B | $4.0B |
| P/E Ratio → | -3.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.03 | 6.80 | 8.10 | 8.92 | 16.22 | 31.08 | 23.30 | 42.03 | 753.82 | 20927.48 | — |
| P/B Ratio | 8.07 | 14.52 | 12.77 | 9.19 | 6.18 | 7.30 | 3.70 | 3.55 | 5.13 | 5.87 | 7.77 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.56 | 7.71 | 8.64 | 15.47 | 28.62 | 19.47 | 39.83 | 715.35 | 19716.06 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Ultragenyx Pharmaceutical Inc. earns an operating margin of -95.7%. Operating margins have expanded from -178.6% to -95.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -211.7% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.3% | 86.3% | 89.6% | 92.2% | 95.4% | 97.7% | 91.3% | 97.8% | 100.0% | -137647.4% | — |
| Operating Margin | -95.7% | -95.7% | -131.1% | -178.6% | -108.6% | -121.8% | -409.0% | -721.2% | -12593.5% | -186471.4% | — |
| Net Profit Margin | -101.6% | -101.6% | -139.7% | -194.7% | -129.2% | -68.8% | -388.3% | -383.7% | -11567.3% | -184867.7% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -211.7% | -211.7% | -193.2% | -111.0% | -43.7% | -20.6% | -63.8% | -39.8% | -70.5% | -48.9% | -40.7% |
| ROA | -38.0% | -38.0% | -40.0% | -46.1% | -27.7% | -12.9% | -43.4% | -32.7% | -58.6% | -44.7% | -38.4% |
| ROIC | -343.7% | -343.7% | -239.7% | -107.2% | -50.0% | -66.4% | -84.5% | -71.6% | -82.8% | -49.6% | -37.0% |
| ROCE | -45.2% | -45.2% | -45.6% | -49.4% | -26.2% | -25.4% | -50.6% | -69.8% | -73.1% | -49.0% | -41.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $174M exceeds total debt of $40M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.16 | 0.09 | 0.05 | 0.04 | 0.06 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.51 | -0.62 | -0.29 | -0.29 | -0.58 | -0.61 | -0.19 | -0.26 | -0.34 | -0.18 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.50 | -8.50 | -8.62 | -15.09 | -12.97 | -9.92 | -373.72 | — | — | — | — |
Net cash position: cash ($174M) exceeds total debt ($40M)
Short-term solvency ratios and asset-utilisation metrics
Ultragenyx Pharmaceutical Inc.'s current ratio of 2.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.38x to 2.37x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | 2.37 | 2.61 | 3.38 | 4.72 | 6.83 | 8.24 | 6.99 | 3.44 | 8.27 | 16.13 |
| Quick Ratio | 2.24 | 2.24 | 2.49 | 3.28 | 4.63 | 6.76 | 8.13 | 6.90 | 3.43 | 8.27 | 16.13 |
| Cash Ratio | 1.77 | 1.77 | 2.06 | 2.86 | 4.08 | 6.34 | 7.31 | 6.15 | 3.30 | 6.31 | 15.65 |
| Asset Turnover | — | 0.37 | 0.29 | 0.24 | 0.23 | 0.15 | 0.09 | 0.07 | 0.01 | 0.00 | — |
| Inventory Turnover | 1.70 | 1.70 | 1.33 | 1.06 | 0.99 | 0.47 | 0.78 | 0.16 | 0.00 | — | — |
| Days Sales Outstanding | — | 79.36 | 61.69 | 40.63 | 29.53 | 31.10 | 115.59 | 90.30 | 722.73 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ultragenyx Pharmaceutical Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $91M | $74M | $70M | $68M | $61M | $57M | $50M | $42M | $40M | $37M |
Compare RARE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RAREYou | $2B | -3.7 | — | — | 86.3% | -95.7% | -211.7% | -343.7% | — |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RARE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonUltragenyx Pharmaceutical Inc.'s current P/E ratio is -3.7x. This places it at the 50th percentile of its historical range.
Ultragenyx Pharmaceutical Inc.'s return on equity (ROE) is -211.7%. The historical average is -74.7%.
Based on historical data, Ultragenyx Pharmaceutical Inc. is trading at a P/E of -3.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ultragenyx Pharmaceutical Inc. has 86.3% gross margin and -95.7% operating margin.